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Abstract
Background: Pim family kinases are small constitutively active serine/threonine-specific kinases, elevated levels of
which have been detected in human hematopoietic malignancies as well as in solid tumours. While we and others
have previously shown that the oncogenic Pim kinases stimulate survival of hematopoietic cells, we now examined
their putative role in regulating motility of adherent cancer cells. For this purpose, we inhibited Pim kinase activity
using a small molecule compound, 1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde (DHPCC-9), which we had
recently identified as a potent and selective inhibitor for all Pim family members.
Results: We now demonstrate that the Pim kinase inhibitor DHPCC-9 is very effective also in cell-based assays.
DHPCC-9 impairs the anti-apoptotic effects of Pim-1 in cytokine-deprived myeloid cells and inhibits intracellular
phosphorylation of Pim substrates such as Bad. Moreover, DHPCC-9 slows down migration and invasion of cancer
cells derived from either prostate cancer or squamocellular carcinoma patients. Silencing of Pim expression reduces
cell motility, while Pim overexpression enhances it, strongly suggesting that the observed effects of DHPCC-9 are
dependent on Pim kinase activity. Interestingly, DHPCC-9 also abrogates NFATc-dependent migration of cancer
cells, implying that NFATc factors mediate at least part of the pro-migratory effects of Pim kinases.
Conclusions: Altogether, our data indicate that DHPCC-9 is not only a powerful tool to investigate physiological
effects of the oncogenic Pim family kinases, but also an attractive molecule for drug development to inhibit
invasiveness of Pim-overexpressing cancer cells.
Background
The mammalian Pim family of serine/threonine-specific
kinases consists of three highly homologous proteins,
Pim-1, Pim-2 and Pim-3, whose functions and expres-
sion patterns are partially overlapping [1,2]. Crystalliza-
tion studies have revealed that Pim kinases
constitutively reside in an active conformation [3], so
that their activities are mainly regulated at the level of
expression. In hematopoietic cells pim expression is
transiently induced by a number of cytokines including
several types of interleukins (IL; [4-6]). When overex-
pressed in mice, Pim kinases are oncogenic and can
enhance lymphomagenesis, especially in collaboration
with other oncoproteins such as Myc family members,
Bcl-2 or Gfi-1 [7-10]. Upregulated expression levels for
Pim kinases have been observed not only in human leu-
kemias and lymphomas [11], but also in several types of
solid tumors such as prostate, colon, oral, hepatic and
pancreatic cancers (reviewed in [12,13]).
There are many ways how Pim kinases contribute to
tumorigenesis by promoting proliferation and preventing
apoptosis (reviewed in [13,14]). In hematopoietic cells,
we have previously shown that Pim-1 stimulates activ-
ities of several transcription factors including c-Myb
[15], NFATc1 [16] and the RUNX family proteins [17],
and thereby enhances production of cytokines and other
survival factors. In addition, all Pim family members
inhibit apoptosis by phosphorylating and thereby inacti-
vating the pro-apoptotic Bad protein [18-20]. However,
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solid tumors has remained fairly elusive.
The emerging importance of Pim kinases in human
tumorigenesis has raised growing interest to develop
small molecule inhibitors for them. Several different
classes of Pim inhibitors have recently been reported
(reviewed in [13]), but only a few of them have been
tested in cell-based assays or animal models to demon-
strate anticancer activity [21-27]. In addition, only a
few of them are effective against all Pim family kinases
[21,25-27]. Due to functional redundancy [2], simulta-
neous targeting of all Pim kinases can be of advantage
in treating cancer patients. Yet no severe side effects
a r ee x p e c t e d ,s i n c em i c el a c k i n ga l lt h r e eP i mf a m i l y
members are just slightly deficient in their growth
responses, but otherwise viable and fertile with a nor-
mal life span [2].
In this study, we have further analysed the cellular
effects of 1,10-dihydropyrrolo[2,3-a]carbazole-3-carbal-
dehyde (DHPCC-9) that we recently identified as a
potent and selective inhibitor against all three Pim
family kinases [21]. We now demonstrate that this inhi-
bitor can efficiently block several cellular functions of
Pim kinases. Furthermore, using this inhibitor along
with RNA interference or protein overexpression, we
have been able to reveal an as yet unrecognized role for
all Pim family kinases in promoting migration and inva-
sion of adherent cancer cells.
Methods
Cell lines and culture conditions
The murine IL-3-dependent myeloid FDCP1 cell lines
and the human head and neck squamous cell carci-
noma cell line UT-SCC-12 have been previously
described [28,29]. FDCP1 cell lines and the human
androgen-independent prostate epithelial adenocarci-
noma cell line PC-3 (American Type Culture Collec-
tion) were maintained in RPMI-1640 medium, while
UT-SCC-12 cells were cultured in DMEM medium
with 1% non essential amino acids. All media were
supplemented with 10% fetal bovine serum. 10%
WEHI-conditioned medium w a su s e da st h es o u r c eo f
IL-3 for FDCP1 cell lines.
Cell viability assays
For MTT assays, cell cultures were incubated for 4 h
with 0,5 mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl
tetrazolium bromide (MTT) reagent (Sigma-Aldrich).
Formazan crystals formed during the assays were dis-
solved by acidic isopropanol. Optical densities were
determined by spectrophotometry (Multiscan MCC/340,
Labsystems). Alternatively, cells were stained with Try-
pan blue (Sigma-Aldrich) and live cells excluding the
dye were counted.
Western blotting
Cell pellets were resuspended and lysed in NP-40 lysis
buffer (50 mM Tris, pH 7.5, 10% glycerol, 100 mM
NaCl, 1 mM EDTA, 1% Nonidet P-40 plus protease and
phosphatase inhibitors). After clearing the lysates, pro-
tein concentrations were measured with DC Protein
Assay (Bio-Rad). Twenty to hundred microgram aliquots
of protein were separated by SDS-PAGE, immobilized
onto PVDF-membrane (Millipore) and incubated with
anti-Pim-1 (12H8; Santa Cruz), anti-Pim-2 (D1D2; Cell
Signaling Technology for human protein or
HPA000285; Atlas Antibodies for murine protein), anti-
Pim-3 (D17C9; Cell Signaling Technology), anti-V5
(Invitrogen), anti-Flag or anti-GAPDH (Sigma-Aldrich)
antibodies. Chemiluminescence reactions were generated
by either Amersham™ ECL Plus (GE Healthcare) or
Pierce® ECL (Thermo Scientific) reagents. The signal
intensities were quantified by MCID M5+ Image Analy-
zer (InterFocus, UK).
Cell-based phosphorylation assays
FDCP1 derivatives were transiently transfected with
10 μg of the GST-Bad expression vector (pEBG-mBad;
[19]) using the GenePulser II electroporator (Bio-Rad).
Cells were lysed in buffer containing 10 mM Tris, pH
7.5, 150 mM NaCl, 0,5 mM EDTA, 1% Triton X-100,
10% glycerol and phosphatase inhibitors. Cleared lysates
containing 60 μg aliquots of protein were used to purify
GST-Bad protein with glutathione Sepharose beads (GE
Healthcare) at 4°C. The precipitates were fractionated
by SDS-PAGE and subjected to Western blotting with
anti-Bad and anti-phospho-Bad (Ser
112) antibodies (Cell
Signaling Technology).
Lipofections
For RNA interference, PC-3 cells were transfected with
short interfering RNAs (siRNAs) and Oligofectamine™
(Invitrogen). Non-targeting control siRNA (D-001810-
01-20) or specific siRNAs targeting either pim-1 or pim-
2 (Dharmacon) were used at 100 nM concentration.
These ON-TARGETplus siRNAs have been specifically
designed to reduce off-target effects that may lead to
toxicity or false phenotypes.
For overexpression, Fugene transfection reagents
(Roche) were used to transfect PC-3 cells with 1 μgo f
the pcDNA3.1/V5-HisC vector or its derivatives expres-
sing human pim genes (N.M. Santio, M. Varjosalo,
J. Taipale and P.J. Koskinen, manuscript in preparation),
or 0,25 μg of the pBJ5 vector or pBJ5-NFATc1-FLAG
obtained from S.N. Ho (Stanford University, CA).
Wound Healing assays
Wound healing assays were performed on 24-well plates
either manually or automatically. In manually performed
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while DMSO concentration was maintained at 0,1%.
Scratch wounds were made with a sterile 10 or 200 μl
pipette tip. Photographs were taken using the Zeiss
Stereo Lumar-V12 microscope with the AxioVision
Rel.4.8 software. Percentages of wound healing were cal-
culated by the ImageJ software (Wayne Rasband, NIH,
USA) and the approximate edges of the wounds were
manually marked to figures with straight lines.
For automatic assays with the WoundMaker™ and the
IncuCyte™ systems (Essen Instruments), the scratch
wounds were made with 10 μl sterile pipette tips, after
which fresh culture medium containing 10% or no
serum was added along with either DMSO or 10 μM
DHPCC-9. The IncuCyte™ Scratch Wound software was
used to capture and analyse the pictures. After acquisi-
tion, images were combined with ImageJ into a Quick-
Time movie file.
Boyden chamber invasion assays
Cell culture invasion inserts of 8 μm pore size (BD Bios-
ciences) were coated with Matrigel (100 μg/cm
2;B D
Biosciences) and incubated for 24 h. The assays were
initiated by placing 50 000 cells in DMEM supplemen-
ted with 1% BSA together with either 10 μM DHPCC-9
or 0,1% DMSO. Conditioned medium from confluent
MG-63 human osteosarcoma cells was used as a che-
moattractant to stimulate movement of cells through
the in vitro basement membranes. Cells were incubated
for 72 h, after which insert membranes were fixed for
20 min in 4% paraformaldehyde in PBS and stained with
Mayer’s haematoxylin (Zymed) for 4 h. Then mem-
branes were washed with PBS and cut from the inserts.
Cells on the upper surface of the membrane were wiped
off and membranes were mounted with glycerol and
PBS (9:1, Merck KGaA). Invaded cells on the lower sur-
faces of the membranes were counted.
Statistical analyses
The statistical significance of data was determined by
pairwise comparisons between control samples and trea-
ted samples by using Student’s t-test (Paired Two Sample
for Means). Results were interpreted as highly signifi-
cant*** (p < 0.001), significant** (p < 0.01), weakly signifi-
cant* (p < 0.05) or not significant
ns (p > 0.05). IC50 values
of DHPCC-9 in FDCP-1 cells were determined using
nonlinear regression fitting with the GraphPad Prism
v.5.0. Error bars in all graphs represent SD values.
Results
DHPCC-9 abrogates the anti-apoptotic effects of
Pim-1 in cytokine-deprived myeloid cells
To identify cellular inhibitors for Pim family kinases, we
tested in cell-based assays a panel of small molecule
compounds that we and others had recently shown to
selectively inhibit Pim kinases under in vitro conditions
([21] and unpublished data by the European Union Pro-
kinase Research Consortium). For this purpose, we used
IL-3-dependent FDCP1 cell lines stably expressing either
neomycin (FD/Neo) or the 44 kD isoform of Pim-1 (FD/
Pim44). We had previously shown that survival of
FDCP1-derived cell lines in the absence of IL-3 is
strictly dependent on continuous expression and activity
of either Pim-1 or Pim-2 [18,19,28], so we expected a
Pim-specific inhibitor to abrogate the protective effects
of Pim kinases. To quantitate the effects of the inhibi-
tors on cellular viability, we used the MTT assay, which
measures metabolic activity, but which has been com-
monly used to analyse e.g. cytotoxic effects of various
compounds [30].
When FDCP1 derivatives were cultured for 24 h in
serum-containing growth medium in the presence of 10
μM compounds dissolved in DMSO, most of them did
not have any effects on survival of either FD/Neo or
FD/Pim44 cells or reduced viability of both cell lines to
a similar extent (data not shown). However, one of the
compounds designated DHPCC-9 (1,10-dihydropyrrolo
[2,3-a]carbazole-3-carbaldehyde; [21]; Figure 1A) com-
pletely removed the survival advantage of Pim-1-overex-
pressing cells (Figure 1B). No major changes were
observed in the viability of DHPCC-9-treated FD/Neo
cells as compared to DMSO-treated samples, indicating
that the inhibitor has no general cytotoxic effects in
these cells. By contrast, in FD/Pim44 cells there was a
significant decrease in the viability of inhibitor-treated
cells in the presence and especially in the absence of IL-
3, indicating that DHPCC-9 is indeed a potent cellular
inhibitor that can enter the cells and efficiently impair
the anti-apoptotic effects of Pim-1.
To determine the effective dosage of DHPCC-9 in
FDCP1 derivatives, cells were cultured with increasing
concentrations of the inhibitor in the absence of IL-3 and
analysed 24 h later by the MTT assay. As shown in Fig-
ure 1C, the initially two-fold higher viability rate of FD/
Pim44 cells as compared to FD/Neo cells was lost already
with fairly low amounts of DHPCC-9, with the viability
curves converging at around the 10 μM concentration
used in Figure 1B. Moreover, calculation of the IC50
values indicated that they were nearly similar in both FD/
Neo (6.0 μM) and FD/Pim44 (4.7 μM) cell lines.
To confirm that the results obtained with the MTT
assay reflected cell survival, we stained cells with Trypan
blue and counted dye-excluding live cells at multiple
time-points after withdrawal of IL-3. As shown in Figure
1D, FD/Pim44 cells treated with DMSO were still alive
after 72 h, while FD/Neo cells stopped growth and
started to die already after 12 h. However, when cells
were treated with 10 μM DHPCC-9, the protective
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completely lost and the FD/Pim44 cells behaved like
DMSO-treated FD/Neo control cells. In this assay,
DHPCC-9 also reduced the viability of FD/Neo cells,
which is in line with our previous observations from
FDCP1 cells expressing a dominant negative mutant of
Pim-1 [28].
DHPCC-9 inhibits cellular phosphorylation of Pim
substrates such as Bad
We had recently shown that DHPCC-9 inhibits kinase
activities of all three Pim family proteins under in vitro
conditions [21]. In order to demonstrate that DHPCC-9
similarly inhibits intracellular activities of Pim kinases,
we analysed the phosphorylation status of one of the
well-established Pim substrates, the pro-apoptotic Bad
protein [18-20]. FD/Neo and FD/Pim44 cells were tran-
siently transfected with a GST-Bad expression vector.
Part of the cells were collected 24 h after transfection,
while the rest were grown for 8 h in the absence of IL-
3, but with increasing concentrations of DHPCC-9.
In the absence of IL-3, Ser
112 o fB a dr e m a i n e dm o r e
pronouncedly phosphorylated in FD/Pim44 cells than in
FD/Neo cells (Figure 2A), which was well in line with our
previous results [19]. However, exposure of FD/Pim44
cells to increasing concentrations of DHPCC-9 led to a
significant reduction in the level of Bad Ser
112 phosphor-
ylation as compared to Bad expression levels (Figure 2A).
We also measured Pim protein levels from the cell lysates
and noticed that all three Pim family members were
expressed there and that DHPCC-9 did not reduce their
expression levels either in the presence or absence of IL-
3 (Figure 2B, C). Thus, our results suggest that DHPCC-
9 exerts its cellular effects by inhibiting kinase activities
of all Pim family members towards their downstream tar-
gets. Interestingly, while the endogenous expression
levels of both Pim-1 and Pim-3 proteins were signifi-
cantly reduced by IL-3 withdrawal, the levels of Pim-2
remained unchanged (Figure 2B), suggesting that its
expression in FDCP1 cells may be regulated in a distinct
fashion from the two other family members.
Pim kinases promote cancer cell migration and invasion
During our recent studies we had obtained hints that
Pim kinases may be involved in regulation of cell moti-
lity. Migration of cells is important for many
Figure 1 DHPCC-9 inhibits Pim-1-dependent survival of cytokine-deprived myeloid cells. (A) Schematic structure of 1,10-dihydropyrrolo
[2,3-a]carbazole-3-carbaldehyde (DHPCC-9). (B) FDCP1 cell lines stably expressing neomycin (FD/Neo) or Pim-1 (FD/Pim44) were cultured for 24
h with or without IL-3 in the presence of DMSO or 10 μM DHPCC-9, after which cell viability was analysed by the MTT assay. Graph represents
means from three independent experiments with duplicate samples. (C) Cells were cultured for 24 h without IL-3 in the presence of increasing
concentrations of DHPCC-9. Cell viability was analysed by the MTT assay and IC50 values were determined. Points represent means from four
independent experiments with duplicate samples. (D) Cells grown in the absence of IL-3 were stained with Trypan blue and live cells were
counted at the indicated time-points. Points represent means from triplicate determinations from one of two similar experiments.
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w o u n dh e a l i n ga n di m m u n er e s p o n s e s ,b u ti ti sa l s o
essential for tumor angiogenesis and metastasis. There-
fore we decided to use DHPCC-9 as a tool to investi-
gate the possibility that Pim kinases affect migration of
adherent cancer cells. When we carried out scratch
wound assays with PC-3 prostate cancer cells, we
noticed that DHPCC-9 decreased the motility of those
cells in a dose-dependent fashion (Figure 3A, B), but
did not reduce endogenous expression levels of Pim
kinases (Figure 3C). Viability of PC-3 cells also
remained unaffected by DHPCC-9, as measured both
by the MTT assay (Figure 3D) and by Trypan blue
staining (Figure 3E).
The inhibitory effects of DHPCC-9 on cell migration
were not restricted to PC-3 cells, since similar results
were obtained also from UT-SCC-12A squamocellular
carcinoma cells (Figure 4A, B). We have previously
shown that these cells express high levels of Pim-1 [29],
but we now demonstrated that they also express Pim-2
and Pim-3 (Figure 4C). Similarly to PC-3 cells, DHPCC-
9 did not decrease either Pim expression levels (Figure
4C) or viability (Figure 4D) of UT-SCC-12A cells.
To further prove that the inhibitory effects of
DHPCC-9 on cell motility were mediated via specific
inhibition of Pim kinase activity, we carried out wound
healing assays in PC-3 cells in the presence of short
interfering RNAs (siRNAs) targeting either Pim-1, Pim-2
or both. Pim-3 was not targeted, since its expression
levels have been reported to be significantly lower in
PC-3 cells than those for Pim-1 and Pim-2 [27]. A larger
tip was now used to scratch the wounds to facilitate fol-
low-up of the wound healing processes. While wounds
in control cells transfected with non-targeting (nt)
siRNA healed within 48 h, those expressing the Pim-
specific siRNAs recovered significantly more slowly (Fig-
ure 5A, B). These results were not due to differences in
cell viability, as confirmed by the MTT assay (data not
shown). Most striking reduction in migration was
observed when both Pim-1 and Pim-2 were silenced. In
fact, the effects of simultaneously silenced Pim-1 and
Pim-2 were initially comparable to those observed in
control transfectants treated with DHPCC-9. However,
the effects of DHPCC-9 were more sustainable, since
they were visible even after the 48 h time-point (Figure
5 A ,Ba n dd a t an o ts h o w n ) .H e r ei ts h o u l da l s ob e
noted that the siRNA transfection efficiency was
approximately 25% (data not shown), so only partial
silencing of Pim kinases was received, as demonstrated
by Western blotting (Figure 5C).
To follow-up the wound healing process in more detail
and to compare the effects of DHPCC-9 in the presence
or absence of serum, we used the IncuCyte™ imaging
Figure 2 DHPCC-9 represses intracellular phosphorylation of
Bad by Pim kinases. Cells were transiently transfected with the
GST-Bad expression vector. At 24 h after transfection, IL-3 was
withdrawn and cells were treated with DMSO or increasing
concentrations of DHPCC-9 for indicated time-points. (A) GST-Bad
was precipitated and its phosphorylation and expression levels were
analysed by Western blotting. The intensities of phosphorylated
versus total samples of Bad protein were quantitated and the
relative intensities of Bad phosphorylation in inhibitor-treated
samples as compared to DMSO-treated control sample were
calculated. Endogenous Pim expression levels in Bad-transfected (B)
or untransfected (C) FDCP1 derivatives were determined by Western
blotting with specific antibodies against distinct Pim family
members. GAPDH staining was used as a loading control.
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of 10% serum, we obtained very similar results as in man-
ual experiments, while removal of serum reduced cell
migration rates (Additional File 1). Due to the lower
migration rates of serum-deprived cells, it was possible to
follow the movements of individual cells in movies con-
structed from the slides produced by the IncuCyte™
(Additional File 2). There DHPCC-9-treated cells seemed
to have totally lost their ability to move, whereas only a
few of the control cells seemed equally immotile.
To determine whether Pim kinases are able to affect
invasive properties of PC-3 cells, we carried out Boyden
chamber assays with PC-3 cells that had been trans-
fected with non-targeting or Pim-specific siRNAs and
treated with either DMSO or DHPCC-9. Three days
later, cells were fixed and stained to facilitate counting
of invaded cells. As summarized in Figure 5D, silencing
of Pim-1 and Pim-2 reduced the rate of invasion of PC-
3 cells. However, even more striking effects were
obtained in the presence of DHPCC-9, which allowed
only a minority of the cells to move through the
membranes.
To obtain even more evidence to support our conclu-
sion that Pim kinases enhance cell motility, we transi-
ently overexpressed them in PC-3 cells and subjected
cells to wound healing assays in the absence or presence
of DHPCC-9. Indeed, cells overexpressing any of the
three Pim family members migrated remarkably faster
than mock-transfected control cells (Figure 6A left
panel). Furthermore, DHPCC-9 reduced the migration
rates of Pim-transfected cells almost to the levels of the
control cells (Figure 6A right panel). As summarized in
Figure 6B, the enhancing effects of Pim kinases on cell
migration were comparable with each other, even
Figure 3 DHPCC-9 decreases migration of prostate cancer cells without affecting Pim protein levels or cell viability.P C - 3p r o s t a t e
cancer cells were treated with DMSO or 10 μM DHPCC-9. Two hours later, scratch wounds were made with a 10 μl sterile pipette tip. (A)
Representative pictures were taken at indicated time-points and analysed. (B) Graph represents means from triplicate samples after 24 h
incubation. (C) Endogenous Pim expression levels were determined by Western blotting. GAPDH staining was used as a loading control. (D) Cell
viability was analysed by the MTT assay. (E) The amount of live cells was determined by Trypan blue staining.
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(Figure 6C). As in the case of endogenous Pim expres-
sion, DHPCC-9 did not reduce expression of the V5-
tagged Pim proteins (Figure 6C). Moreover, when trans-
fected cells were subjected to MTT assay, no major
changes were observed (data not shown), indicating that
the effects of Pim kinases on PC-3 cell motility were not
due to enhanced proliferation. In conclusion, our data
with the Pim inhibitor as well as the Pim-specific siR-
NAs and overexpression constructs suggest that the
expression and activity of Pim family kinases are essen-
tial for both migration and invasion of adherent cancer
cells.
DHPCC-9 inhibits pro-migratory effects of one
of the Pim substrates, NFATc1
We next wanted to address the possibility that the
effects of Pim kinases on cell motility are at least
partially mediated via NFATc transcription factors that
we have previously identified as Pim targets [16]. This
was of interest, since there is endogenous NFATc activ-
ity in PC-3 cells [31] and since NFATc factors have
recently been implicated in cancer cell migration and
invasion [32].
When we transiently overexpressed FLAG-tagged
NFATc1 in PC-3 cells and subjected cells to wound
healing assays in the absence or presence of DHPCC-9,
we observed that cells overexpressing NFATc1 healed
significantly faster than mock-transfected cells (Figure
7A-B). Yet cell viability or Pim expression levels were
not affected by NFATc1 overexpression, as demon-
s t r a t e db yT r y p a nb l u es t a i n ing and Western blotting,
respectively (data not shown), indicating that the effects
of NFATc1 on PC-3 cell migration were not due to
enhanced proliferation or Pim expression. More inter-
estingly, the Pim kinase inhibitor DHPCC-9 was able to
Figure 4 DHPCC-9 also reduces migration of squamocellular carcinoma cells. UT-SCC-12-A squamocellular carcinoma cells were treated
with DMSO or 10 μM DHPCC-9. Two hours later, scratch wounds were made with a 10 μl sterile pipette tip. (A) Representative pictures were
taken at indicated time-points and analysed. (B) Graph represents means from triplicate samples. (C) Endogenous Pim expression levels were
determined by Western blotting. GAPDH staining was used as a loading control. (D) Cell viability was analysed by the MTT assay.
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Page 7 of 13Figure 5 Silencing and inhibition of Pim kinases both repress migration and invasion of prostate cancer cells.P C - 3c e l l sw e r e
transfected with 100 nM non-targeting (nt) control siRNA or siRNA oligonucleotides targeting pim genes, and incubated overnight. (A) For
wound healing assays, transfected cells were moved onto 24-well plates and allowed to attach for 24 h, after which DMSO or 10 μM DHPCC-9
was added and scratch wounds were made with a sterile 200 μl pipette tip. Representative pictures were taken at indicated time-points and
analysed. (B) Graph represents means of three independent experiments with duplicate samples. (C) Efficiency of Pim kinase silencing was
determined by Western blotting. GAPDH staining was used as a loading control. Non-parallel lanes from a single electrophoresis gel are
separated by dash lines. (D) For invasion assays, transfected cells were placed in invasion inserts together with either DMSO or 10 μM DHPCC-9.
MG-63-conditioned medium was used as a chemoattractant to induce invasion. Cells were incubated for 72 h, after which insert membranes
were fixed and stained. Invasion assays were repeated for three times and invaded cells were counted from each sample from 10 representative
fields. Shown are means of duplicate samples from one representative experiment.
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same extent as of the control cells (Figure 7A-B), while
it did not significantly affect the expression levels of
FLAG-tagged NFATc1 (Figure 7C). Thus, these results
suggest that Pim kinases promote cancer cell migration
by regulating activity of NFATc transcription factors.
Discussion
In this study, we have characterized the biological effects
of 1,10-dihydropyrrolo[2,3-a]carbazole-3-carbaldehyde
(DHPCC-9) and demonstrated that it is an efficient cell-
permeable inhibitor targeting all human or murine Pim
family kinases. We have shown that DHPCC-9 abrogates
the anti-apoptotic effects of Pim-1 in cytokine-deprived
FDCP1 myeloid cells, while it does not display general
cytotoxicity at the micromolar concentrations used.
DHPCC-9 treatment also inhibits intracellular phos-
phorylation of Pim substrates such as Bad. Furthermore,
we have been able to use DHPCC-9 as a tool to reveal a
novel function for Pim kinases in regulation of motility
of adherent cancer cells. Treatment with DHPCC-9 sig-
nificantly slows down migration of both PC-3 prostate
cancer cells and UT-SCC-12A squamocellular carci-
noma cells, but does not significantly affect metabolic
activity or viability of these cells or their levels of Pim
expression. In addition, DHPCC-9 efficiently inhibits
invasion of PC-3 cells through matrigel.
The observed effects of DHPCC-9 are most likely
dependent on its ability to inhibit Pim kinase activity,
since similar results were obtained by silencing Pim
expression by RNA interference. In addition, overexpres-
sion of any Pim family member has opposite effects by
Figure 6 Pim kinase overexpression promotes migration of prostate cancer cells. PC-3 cells were transiently transfected with an empty
vector (Mock) or vectors expressing V5-tagged Pim-1, Pim-2 or Pim-3. DMSO or 10 μM DHPCC-9 were added 24 h after transfection. The wound
healing assays were initiated 2 h later by scratching the wounds with a sterile 200 μl pipette tip. (A) Shown are representative pictures from
three time-points. (B) Graph represents means of triplicate samples. (C) Levels of overexpressed Pim kinases were determined by Western
blotting with anti-V5 antibody. GAPDH staining was used as a loading control.
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that Pim kinases are potent regulators of cellular pro-
cesses involved in migration and/or invasion.
In all of our assays, the effects of DHPCC-9 were
more pronounced than those of Pim-specific siRNAs,
most likely due to the longer half-life and better cellular
penetrance of the inhibitor. Indeed, when the stability of
DHPCC-9 dissolved in the growth medium of PC-3
cells was analysed by liquid chromatography, no detect-
able degradation of the compound was observed within
the time-periods used in our assays (unpublished data).
By contrast, siRNAs affect only a portion of cells
depending on transfection efficiency and their transient
effects are rapidly diluted within the few days after
transfection. Here it should also be noted that while
DHPCC-9 is able to target all the three Pim kinases
endogenously expressed in PC-3 cells, Pim-3 remains
active in cells treated with the combination of siRNAs
against Pim-1 and Pim-2. Yet in PC-3 cells the expres-
sion levels for Pim-3 have been reported to be signifi-
cantly lower than for the two other family members
[27]. Thus, even though all Pim kinases may be equally
capable of enhancing cell motility, the magnitude of
their redundant effects is likely to depend on their
dosage in each cell type.
An intriguing feature of Pim family kinases is that
they are constitutively active with a unique hinge region
containing a proline residue, which allows only one
hydrogen bond to be formed with ATP [3]. According
to crystallization studies [21], DHPCC-9 does not bind
to the hinge region as some other ATP-mimetic Pim
inhibitors do [33,34]. By contrast, it competes with ATP
for binding to the conserved lysine residue correspond-
ing to Lys67 in Pim-1 [21]. This residue is known to be
critical for Pim kinase activity, since its mutation e.g. to
methionine results in production of a kinase-deficient
protein [16].
Under in vitro conditions, we have previously demon-
strated that DHPCC-9 is highly potent against Pim-1,
Pim-2 and Pim-3 kinases with very low IC50 values of
1 2 ,5 1a n d1 0n M ,r e s p e c t i v e l y[ 2 1 ] .I ti sa l s oh i g h l y
selective, since with the 10 μM concentration used in
most of our cellular assays, the in vitro activities of Pim-
1, Pim-2 and Pim-3 kinases are inhibited by 98, 93 and
99%, respectively, while all the other 88 kinases tested
remain fairly active ([21] and unpublished data). Yet we
cannot fully exclude the possibility that some of the
observed effects of DHPCC-9 are enhanced by its mod-
erate ability to inhibit also other kinases. Interestingly,
DHPCC-9 seems to target Pim-1 and Pim-3 slightly
more efficiently than Pim-2. This selectivity is in line
with similar observations from several other Pim inhibi-
tors, as recently discussed [13]. Even though Pim-1 and
Pim-3 are more closely related to each other than to
Figure 7 Enhancing effects of NFATc1 on migration of prostate cancer cells are abolished by DHPCC-9.P C - 3c e l l sw e r et r a n s i e n t l y
transfected with an empty vector (Mock) or a vector expressing FLAG-tagged NFATc1. DMSO or 10 μM DHPCC-9 were added 24 h after
transfection. The wound healing assays were initiated 2 h later by scratching the wounds with a 10 μl sterile pipette. (A) Shown are
representative pictures from three time-points. (B) Graph represents means of two similar experiments with triplicate samples. (C) Overexpression
of NFATc1 was confirmed by Western blotting with anti-FLAG antibody. GAPDH staining was used as a loading control.
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Page 10 of 13Pim-2, structural models are unable to explain the
observed differences in their sensitivities.
In cell-based assays, the activities of inhibitors are not
expected to be as high as under in vitro conditions with
purified compounds. Thus, the micromolar IC50 values
observed in FD/Neo (6.0 μM) and FD/Pim44 (4.7 μM)
cells can be considered promising, especially since they
were obtained using complete medium containing 10%
serum. Cytotoxicity assays with some other Pim inhibi-
tors have been carried out in the presence of lower or
no serum levels [22,27], which probably has decreased
the viability of the cells and also enhanced bioavailability
of the inhibitors and consequently lowered their IC50
values. Indeed, more pronounced effects were observed
also in our assays with DHPCC-9, when cells were
grown in the absence of serum.
Yet it is likely that the efficiency of the Pim inhibitor
can be further improved by using DHPCC-9 as a scaffold
for production of additional, more potent derivatives,
which could be useful not only as research tools, but also
as lead compounds in development of drugs against Pim-
overexpressing tumors. Since DHPCC-9 has been shown
to be highly efficient in reducing the motility of Pim-
overexpressing cancer cells, derivatives of DHPCC-9
might be able to prevent tumor metastasis and/or angio-
genesis. Moreover, since we and others have recently
shown that Pim kinases are involved in development of
resistance against radiation therapy or chemotherapy
[29,35], combinations of Pim inhibitors together with
other anticancer therapy methods are expected to lead to
most efficient therapeutic approaches.
Even though Pim kinases have been implicated to have
prognostic roles in several types of solid cancer, there is
still controversy in the literature on whether or not high
levels of Pim expression are of disadvantage for prostate
cancer patients (reviewed in [12,13]). This may be partly
due to heterogeneity of the samples and to the fact that
in none of the studies published so far have expression
levels for all three Pim kinases been analysed in parallel.
It is also clear that overexpressed Pim kinases alone are
unable to transform cells, but require collaboration e.g.
with Myc oncoproteins. Interestingly in this regard,
coexpression of Pim-1 and c-Myc in human prostate
tumors has recently been associated with higher Gleason
grades than overexpression of either one alone, suggest-
ing that these oncoproteins synergize to induce
advanced prostate carcinoma [36].
While our work was in progress, silencing of Pim-3
was reported to reduce endothelial cell spreading,
migration and vascular tube formation [37], providing
further support to our hypothesis that Pim kinases can
stimulate metastatic and/or angiogenic potential of can-
cerous cells. In addition, Pim-1 but not Pim-2 was
shown to regulate homing and migration of bone
marrow cells, possibly via phosphorylation-mediated
modification of CXCR4 expression on cell surface [38].
Yet the exact substrates and signalling pathways that all
three Pim kinases regulate to enhance motility of adher-
ent cancer cells remain to be elucidated. Interestingly,
the NFATc transcription factors that we have previously
identified as Pim targets [16] have recently been impli-
cated in tumor cell migration and invasion as well as
tumor angiogenesis (reviewed in [39]). Constitutively
active NFATc isoforms have been shown to promote
induction and progression of both hematological malig-
nancies and solid tumors by driving synthesis and secre-
tion of pro-angiogenic factors (e.g. cyclo-oxygenase 2
and tissue factor) as well as factors promoting cell moti-
lity (e.g. lysophosphatic acid and prostaglandin E2).
Thus, these NFATc-dependent effects are expected to
be enhanced in tumor cells overexpressing Pim kinases.
Indeed, our data indicate that Pim inhibitors can block
the pro-migratory effects of NFATc factors in prostate
cancer cells, suggesting that regulation of NFATc activ-
ity may be one of the mechanisms how Pim kinases pro-
mote cancer cell motility.
Conclusions
Altogether, our data indicate that Pim kinases can sti-
mulate migration and invasion of adherent cancer cells,
possibly via NFATc factors. Therefore, the novel Pim
kinase inhibitor DHPCC-9 is not only an efficient tool
for Pim research, but also a promising compound for
cancer drug development and could be targeted espe-
cially to inhibit invasiveness of Pim-overexpressing can-
cer cells.
Additional material
Additional file 1: DHPCC-9 decreases PC-3 cell migration both in
the presence and absence of serum. PC-3 cells were plated on 24-well
Essen ImageLock plates. Scratch wounds were made 24 h later by the
Essen WoundMaker™ with a sterile 10 μl Eppendorf pipette tip.
Thereafter fresh culture medium containing 10% or no serum along with
either DMSO or 10 μM DHPCC-9 was added. Essen IncuCyte™ Scratch
Wound software was used to capture pictures and to analyse the wound
confluences. (A) Graph represents means of triplicate samples. (B) Shown
are representative pictures from five time points.
Additional file 2: DHPCC-9 decreases PC-3 cell migration both in
the presence and absence of serum. A movie file was produced from
PC-3 scratch wound samples described in the Additional File 1. Pictures
taken by the IncuCyte™ Scratch Wound software were combined into a
QuickTime movie file with ImageJ. Shown are representative wound
healing movies of PC-3 cells treated with DMSO (A, C) or DHPCC-9 (B,
D) and cultured in medium containing 10% serum (A, B) or no serum
(C, D).
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